|
|
|
|
Ulcerative Colitis - APRISOTM Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Coliti
Salix Pharmaceuticals, Ltd.(NASDAQ: SLXP) announced that the (FDA) has granted marketing approval for APRISO (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting aminosalicylate indicated for the maintenance of...
|
|
|
Colitis cystica profunda
Martin JK et al.- A review of records of patients seen at the Mayo Clinic produced 66 clinical cases of localized colitis cystica profunda, and in 21 patients the diagnosis was confirmed histologically. Follow-up, which was available in...
|
|
|
APRISOTM Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
- (NewsRx.com) -- Salix Pharmaceuticals, Ltd.(NASDAQ: SLXP) announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO (mesalamine) extended-release capsules 0.375 g. APRISO is a locally...
|
|
|
GARDASIL(R), Merck's Cervical Cancer Vaccine, Demonstrated Efficacy in Preventing HPV-Related Disease in Males
GARDASIL[Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], the cervical cancer vaccine from Merck & Co., Inc., prevented 90 percent of external genital lesions caused by human papillomavirus (HPV)...
|
|
|
Progression to Colorectal Neoplasia in Ulcerative Colitis: Effect of Mesalamine
Ullman T et al.- In long-standing UC, patients with fLGD have a higher rate of progression to advanced neoplasia than those with NoD or IND. However, at none of these stages of disease did mesalamine use show definitive chemopreventive...
|
|
|
[Diagnosis in Oncology] Extragonadal Choriocarcinoma in Ulcerative Colitis
This Article Google Scholar Avanthi Ragam1, Seema Apichai2, Abhilasha Radhakrishnan1, Miguel Gonzalez2, Timothy Laurie3, and Chadi Nabhan4 1 Department of Medicine, Division of Hematology and Oncology, Lutheran General Hospital, Park Ridge,...
|
|
|
Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From
/PRNewswire/ -- A study published today in the Journal of Occupational and Environmental Medicine found that annual medical expenditures for Crohn's disease patients are more than three times higher than those for a matched comparison group...
|
|
|
Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From
/PRNewswire/ -- A study published today in the Journal of Occupational and Environmental Medicine found that annual medical expenditures for Crohn's disease patients are more than three times higher than those for a matched comparison group...
|
|
|
Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From
ANN ARBOR, Mich., Nov.10 /PRNewswire/ -- A study published today in the Journal of Occupational and Environmental Medicine found that annual medical expenditures for Crohn's disease patients are more than three times higher than those for...
|
|
|
Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From
ANN ARBOR, Mich., Nov.10 /PRNewswire/ -- A study published today in the Journal of Occupational and Environmental Medicine found that annual medical expenditures for Crohn's disease patients are more than three times higher than those for...
|
|
|
Idera Pharmaceuticals Reports Third Quarter 2008 Financial Results
-Idera Pharmaceuticals, Inc.(Nasdaq: IDRA) today reported financial results for the third quarter and nine months ended September 30, 2008. We are pleased that our business strategy is allowing us to advance multiple therapeutic...
|
|
|
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Programs; Announces Third Quarter 2008 Fin
- Hollis-Eden Pharmaceuticals, Inc.(NASDAQ:HEPH), the world leader in the development of a new class of small molecule compounds based on endogenous steroid hormones, today reported on the Company's progress in its drug development...
|
|
|
Does CT Influence the Decision to Perform Colectomy in Patients with Severe Ulcerative Colitis
Moreira ADL et al.- CT has a minor impact on the decision to perform colectomy in patients with severe acute ulcerative colitis. --- INFLAMMATORY BOWEL DZ TOP ARTICLES --- World Journal of Gastroenterology, 10/02/08 The Lancet...
|
|
|
Apriso Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
- Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting...
|
|
|
SALIX PHARMACEUTICALS LTD EPS Estimated At -1.09: Current Recommendation is Market Perform
Company: SALIX PHARMACEUTICALS LTD Report Headline: 'SLXP: FDA Approves Apriso For Ulcerative Colitis' Report Date: October 31, 2008 Current FY EPS Estimate [FY2008]: -1.09 Previous EPS Estimate for Current FY [FY2008]: -1.09 Current...
|
|
|
SALIX PHARMACEUTICALS LTD EPS Estimated At -1.09: Current Recommendation is Market Perform
Company: SALIX PHARMACEUTICALS LTD Report Headline: 'SLXP: FDA Approves Apriso For Ulcerative Colitis' Report Date: October 31, 2008 Current FY EPS Estimate [FY2008]: -1.09 Previous EPS Estimate for Current FY [FY2008]: -1.09 Current...
|
|
|
Previously Unknown Immune Cell May Help Those with Crohn's and Colitis
Newswise The tonsils and lymphoid tissues in the intestinal tract that help protect the body from external pathogens are the home base of a rare immune cell newly identified by researchers at Washington University School of Medicine in St.
|
|
|
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
Salix Pharmaceuticals, Ltd.(NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0.375 g. APRISO is a locally-acting...
|
|
|
Apriso Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
RALEIGH, NC, November 3 / MARKET WIRE/ -- Salix Pharmaceuticals, Ltd.(NASDAQ: SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO(TM) (mesalamine) extended-release capsules 0...
|
|
|
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
- Salix Pharmaceuticals, Ltd.(NASDAQ:SLXP) today announced that the U.S. Food and Drug Administration (FDA) has granted marketing approval for APRISO Bill Forbes, Pharm. D., Vice President, Research and Development, and Chief...
|
|
|
Salix Pharma Gets FDA Approval to Market APRISO capsules For Ulcerative Colitis Remission Maintenance - Update
Raleigh, North Carolina-based Salix Pharmaceuticals, Ltd.(SLXP: News ) announced that the U.S. Food and Drug Administration, or FDA, has granted marketing approval for APRISO extended-release capsules - a locally acting aminosalicylate ...
|
|
|
Steroid-Loaded Erythrocytes Show Promise for Refractory Ulcerative Colitis
_ Steroid-Loaded Erythrocytes Show Promise for Refractory Ulcerative Colitis.
|
|
|
Modified-Release Mesalazine Effective, Safe, and Useful for Patients With Refractory Ulcerative Colitis: Prese
-- Modified-release mesalazine 4.8 g/day proved equally effective and safe compared to mesalazine 2.4 g/d in the treatment of patients with moderate ulcerative colitis, and could be useful for patients with refractory disease, according to...
|
|
|
Time to Resolution of Symptoms With Mesalazine Depends on Ulcerative Colitis Severity: Presented at UEGW
-- Treatment with mesalazine is effective in patients with ulcerative colitis, but the resolution of symptoms may take a few weeks, especially in patients with more pronounced disease activity, researchers reported here at the 16th United...
|
|
|
Improving the Quality of Living for Patients With Ulcerative Colitis -- A Call to Action
To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View...
|
